Male Hypogonadism Commonly Missed Diagnoses

Why Male Hypogonadism Is So Often Missed

Male hypogonadism shares symptoms with at least half a dozen common conditions, and most clinicians never order a testosterone panel during a first workup for fatigue or low mood. The Endocrine Society's 2018 Clinical Practice Guideline defines symptomatic hypogonadism as total testosterone below 300 ng/dL confirmed on two separate morning blood draws, combined with classic signs and symptoms [1]. Because no single symptom is specific, the diagnosis depends on a deliberate decision to test.

The Symptom Overlap Problem

Fatigue, low libido, depressed mood, difficulty concentrating, and reduced muscle mass all appear in the diagnostic criteria for major depressive disorder (DSM-5), hypothyroidism, obstructive sleep apnea, anemia, and chronic kidney disease. A clinician working through a differential under time pressure can reasonably stop at any one of these and never reach testosterone deficiency.

A 2006 cross-sectional study published in the Journal of Clinical Endocrinology and Metabolism (N=2,162) found that 38.7% of men over 45 seen in primary care had total testosterone below 300 ng/dL, yet fewer than 10% had been evaluated for it [2]. The gap between prevalence and diagnosis rate is substantial.

Why Aging Is Not a Sufficient Explanation

Testosterone does decline with age, roughly 1 to 2% per year after age 30 [3]. Clinicians sometimes attribute low testosterone levels to normal aging and defer treatment. The Endocrine Society guideline explicitly states, however, that age alone does not justify withholding diagnosis or treatment when symptoms are present and biochemistry is consistent [1]. Calling every case of low testosterone in an older man "normal aging" misses a treatable condition.

Condition 1: Major Depressive Disorder

Depression and hypogonadism produce nearly identical symptom profiles. Both cause low energy, anhedonia, poor concentration, and reduced libido. The result is that a large proportion of men with undiagnosed hypogonadism receive antidepressants first.

The Bidirectional Relationship

The relationship runs in both directions. Low testosterone can cause depressive symptoms, and major depression can suppress the hypothalamic-pituitary-gonadal (HPG) axis, lowering LH and FSH output and secondarily reducing testicular testosterone production [4]. A 2019 meta-analysis in JAMA Psychiatry covering 27 randomized trials found that testosterone therapy produced a standardized mean difference of 0.21 in depressive symptom scores compared with placebo, a modest but statistically significant effect (P<0.001) [5].

What to Do Clinically

Any man presenting with depressive symptoms who has not responded to one adequate antidepressant trial within 8 weeks should have a testosterone panel drawn. This is not an alternative to psychiatric evaluation. It is an adjunct step that takes one blood draw and costs under $50 at most commercial labs.

Condition 2: Hypothyroidism

Hypothyroidism causes fatigue, weight gain, cold intolerance, slowed cognition, and depressed mood. All of these overlap with hypogonadism. Clinicians frequently check TSH first, find it elevated, diagnose hypothyroidism, and stop there.

Co-occurrence Is Common

The two conditions co-occur more often than chance would predict. Thyroid hormones modulate sex hormone-binding globulin (SHBG) levels: hypothyroidism lowers SHBG, which artificially raises free testosterone relative to total testosterone and may mask a true deficiency if only total testosterone is measured [6]. Conversely, hyperthyroidism raises SHBG, which can lower calculated free testosterone into the deficient range even when total testosterone looks adequate.

The Correct Testing Sequence

When a man presents with fatigue and low libido, ordering TSH alone is not sufficient. TSH, free T4, total testosterone, SHBG, and calculated free testosterone should be ordered simultaneously. Treating hypothyroidism alone and waiting to see if testosterone symptoms resolve adds months to the diagnostic timeline and leaves the patient symptomatic in the interim.

Condition 3: Obstructive Sleep Apnea

Sleep apnea causes severe fatigue, reduced libido, cognitive fog, and mood changes. Total testosterone is suppressed during nocturnal hypoxia, and men with untreated moderate-to-severe OSA consistently show lower morning testosterone values [7].

OSA as a Cause of Secondary Hypogonadism

OSA does not just mimic hypogonadism; it can cause it. A 2012 study in Sleep Medicine (N=127) found that continuous positive airway pressure (CPAP) therapy for 3 months raised total testosterone by a mean of 72 ng/dL in men with moderate-to-severe OSA and baseline testosterone below 300 ng/dL [8]. This means that treating OSA alone may partially or fully restore testosterone without exogenous hormone therapy.

The Clinical Implication

Men with hypogonadism symptoms who are overweight (BMI above 30), snore, or have an Epworth Sleepiness Scale score above 10 should be referred for overnight polysomnography before testosterone replacement therapy is initiated. Starting TRT while OSA is untreated increases erythrocytosis risk and may worsen apnea events through mechanisms involving upper airway muscle tone.

Condition 4: Type 2 Diabetes and Metabolic Syndrome

Approximately 25 to 40% of men with type 2 diabetes have total testosterone below 300 ng/dL, compared with roughly 12% of age-matched men without diabetes [9]. The mechanism involves insulin resistance suppressing GnRH pulsatility, elevated adipokines from visceral fat aromatizing testosterone to estradiol, and direct Leydig cell dysfunction.

Why Diabetes Providers Miss It

Endocrinologists managing diabetes focus on HbA1c, lipid panels, and renal function. Fatigue and low libido may be attributed to poor glycemic control rather than hypogonadism, and the testosterone panel is never ordered. A 2016 position statement from the American Diabetes Association notes that testosterone deficiency is independently associated with insulin resistance and increased cardiovascular risk, and recommends evaluation in symptomatic diabetic men [9].

The Testosterone-Insulin Resistance Loop

Low testosterone promotes visceral adiposity, which worsens insulin resistance, which further suppresses testosterone. Randomized trials have shown that testosterone therapy in hypogonadal men with type 2 diabetes reduces HbA1c by approximately 0.5 to 0.9% and fasting glucose by 1.3 mmol/L compared with placebo [10]. Correcting hypogonadism may therefore benefit metabolic control, not just sexual function.

Condition 5: Anemia

Iron deficiency anemia, anemia of chronic disease, and pernicious anemia all cause fatigue and cognitive slowing that can be mistaken for or coexist with hypogonadism. Testosterone stimulates erythropoietin production, so hypogonadism itself can produce a mild normocytic anemia with hemoglobin in the 11.5 to 13.0 g/dL range [11].

How to Tell Them Apart

A CBC, ferritin, B12, and reticulocyte count should be part of the initial workup for any fatigued man. If anemia is present, correcting it first and reassessing symptoms makes clinical sense. If testosterone remains low after anemia is treated, hypogonadism should then be the focus. The two conditions are not mutually exclusive.

Condition 6: Hyperprolactinemia

Elevated prolactin suppresses GnRH pulsatility and is a direct cause of secondary hypogonadism. A pituitary adenoma producing prolactin (prolactinoma) is the most common pituitary tumor in men and can present solely as low libido, erectile dysfunction, and fatigue without headache or visual changes until the tumor is large [12].

When to Suspect It

Prolactin should be measured in every man with confirmed low testosterone, particularly if LH and FSH are also low or low-normal (secondary pattern). Total testosterone below 150 ng/dL with inappropriately low gonadotropins warrants MRI of the pituitary regardless of prolactin level. Missing a prolactinoma and starting testosterone without addressing the tumor misses a potentially curable cause and delays dopamine agonist therapy that could restore fertility.

How to Confirm the Diagnosis: Step-by-Step

The Endocrine Society recommends a structured approach that prevents both over- and under-diagnosis [1].

Step 1: Two Morning Draws

Total testosterone must be measured on two separate occasions, both drawn between 7 and 11 a.m. A single low value is not sufficient for diagnosis. Testosterone secretion is pulsatile and follows a circadian rhythm; values drawn in the afternoon may be 15 to 20% lower than morning peaks [1].

Step 2: Free Testosterone When SHBG Is Abnormal

When total testosterone is between 200 and 400 ng/dL, or when SHBG is known to be abnormal (obesity, hypothyroidism, liver disease, exogenous androgens), free testosterone by equilibrium dialysis or a validated calculated method should be obtained. The Vermeulen equation is the most widely accepted calculator [13].

Step 3: LH, FSH, and Prolactin

LH and FSH distinguish primary from secondary hypogonadism. Low testosterone with high LH and FSH indicates primary testicular failure. Low testosterone with low or inappropriately normal LH and FSH indicates a hypothalamic or pituitary problem that requires further imaging and biochemical workup. Prolactin should be checked in every secondary case.

Step 4: Rule Out Reversible Causes

Before initiating TRT, clinicians should check for and address: untreated OSA, opioid use (chronic opioids suppress the HPG axis), glucocorticoid excess, hemochromatosis (serum ferritin and transferrin saturation), and significant acute illness. The Endocrine Society guideline states explicitly that testosterone should not be initiated during acute illness because testosterone values can be transiently suppressed by 20 to 30% [1].

Managing Male Hypogonadism: Treatment Overview

Once confirmed, male hypogonadism has effective pharmacologic treatments. Selection depends on the patient's goals, including fertility preservation, delivery preference, and monitoring tolerance.

Testosterone Replacement Therapy Options

Intramuscular (IM) testosterone cypionate or enanthate: 100 to 200 mg every 1 to 2 weeks, or 75 mg weekly to reduce peak-trough fluctuation. FDA-approved and lowest cost. Hematocrit should be checked at 3 months and 6 months, then annually [14].

Transdermal gels (testosterone 1% or 1.62%): Applied daily. Provides stable serum levels but carries a transfer risk to partners and children. The FDA issued a black-box warning in 2009 regarding secondary exposure in pediatric contacts [14].

Subcutaneous testosterone pellets: Inserted every 3 to 6 months. Produces stable levels but dose is not adjustable once implanted.

Intranasal testosterone (Natesto 4.5%): Three times daily dosing. Preserves intratesticular testosterone and LH to a greater degree than IM or transdermal routes, which is relevant for men who may want to preserve fertility [15].

Monitoring Parameters

The Endocrine Society recommends checking total testosterone 3 to 6 months after initiation, targeting a mid-normal range of 400 to 700 ng/dL. Hematocrit above 54% requires dose reduction or phlebotomy. PSA should be checked at baseline, 3 to 6 months, and annually thereafter in men over 40 [1].

Fertility-Sparing Alternatives

TRT suppresses the HPG axis and reduces intratesticular testosterone, impairing spermatogenesis. Men who want to father children should instead receive:

• Clomiphene citrate 25 to 50 mg every other day (off-label): raises LH and FSH, stimulating endogenous testosterone production. A 2003 study (N=36) showed mean testosterone rising from 230 to 612 ng/dL over 4 months with preserved sperm parameters [16].
• Human chorionic gonadotropin (hCG): mimics LH, stimulates Leydig cells. Used alone or combined with FSH in secondary hypogonadism when fertility is the primary goal.

The decision framework below summarizes the diagnostic and treatment pathway for clinicians:

1. Two morning testosterone draws (7 to 11 a.m.) both below 300 ng/dL AND symptoms present.
2. Obtain LH, FSH, prolactin, SHBG, CBC, ferritin, TSH, free T4.
3. If LH/FSH high: primary hypogonadism. Check karyotype if age <40. Refer to endocrinology or urology.
4. If LH/FSH low/normal: secondary hypogonadism. Check prolactin, MRI pituitary if prolactin elevated or testosterone <150 ng/dL. Rule out OSA, opioids, glucocorticoids, hemochromatosis.
5. Address reversible causes first (OSA, medication, obesity).
6. If fertility desired: clomiphene or hCG-based protocol.
7. If no fertility concern: choose TRT delivery based on patient preference and monitoring feasibility.
8. Recheck testosterone at 3 months, hematocrit at 3 and 6 months, PSA annually in men over 40.

Cardiovascular Safety: What the Evidence Now Shows

The TRAVERSE trial (N=5,246, mean age 63.5 years), published in the New England Journal of Medicine in 2023, was the largest randomized controlled trial to assess cardiovascular outcomes with testosterone therapy in men with hypogonadism and elevated cardiovascular risk. Testosterone gel 1.62% did not increase the rate of major adverse cardiovascular events (MACE) compared with placebo over a median follow-up of 22 months (hazard ratio 0.96, 95% CI 0.78 to 1.17) [17]. The trial did find higher rates of atrial fibrillation, acute kidney injury, and pulmonary embolism in the testosterone arm, which warrants individualized risk assessment.

The Endocrine Society's position, consistent with TRAVERSE, is that TRT is not contraindicated in men with stable cardiovascular disease, but that erythrocytosis (hematocrit above 54%) must be monitored and managed because it increases thrombotic risk [1].

Practical Takeaways for Clinicians

Correct diagnosis requires ordering the test. Total testosterone, drawn on two mornings, is a low-cost, high-yield intervention for any man over 30 presenting with fatigue, low libido, depressed mood, or unexplained loss of lean mass.

The differential diagnosis must include depression, hypothyroidism, OSA, metabolic syndrome, anemia, and hyperprolactinemia, and ideally these should be evaluated in parallel rather than sequentially. Each sequential workup adds weeks to months of delay for the patient.

Treatment selection should account for fertility goals, monitoring access, and comorbidities. The TRAVERSE trial provides reassurance on cardiovascular safety in the largest trial to date, though atrial fibrillation and thromboembolic events deserve individual attention.

Men with secondary hypogonadism (low LH and FSH) and testosterone below 150 ng/dL should have pituitary MRI before TRT is started. Missing a prolactinoma is a serious diagnostic error with straightforward consequences: prolactinomas respond to cabergoline 0.5 to 1.0 mg twice weekly, often restoring testosterone to normal without exogenous hormone therapy within 3 to 6 months [12].